I would suggest that they are paying for ARDs trail which I have...

I would suggest that they are paying for ARDs trail which I have no issue with, it had nothing to do with first agreement. They would have also paid a good chunk to Camago to consult on how to get fast track for ARDS, OSA and TBI accelerated pathways. (Again outside scope of initial agreement)
The initial plan was to sell through SAS now they are gunning for FDA and that doesn’t come cheap.
There is obviously a high level of confidence in the 3 drugs working out for them to spend up big gunning for FDA approval. All trials needed to change to give them a crack at the FDA side as it has more requirements.
SAS sales could be excellent, FDA access changes the game if any of the drugs work out.
Anyway that is my take on it.